Status:
COMPLETED
Prevalence and Incidence of Lassa Virus Infection in Southern Mali
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
Lassa Virus Infection
Eligibility:
All Genders
6-110 years
Brief Summary
Background: The disease Lassa fever mostly affects people in Western Africa. It is very similar to other diseases that cause fever, like malaria and yellow fever. People get Lassa fever from mice inf...
Detailed Description
In West Africa, as many as 300,000 people are infected annually with Lassa virus (LASV), resulting in approximately 5,000 deaths. Most commonly, human infection comes from contact with infected rodent...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Age greater than or equal to 6 months to 99 years.
- Resident of one of the study sites for at least 3 months.
- Able to provide informed consent.
- Agrees to allow storage of samples for future research.
- Additional inclusion criteria for the cross-sectional study (study 1):
- 1\. No plans to relocate before the study end date.
- Additional inclusion criteria for the clinic-based study (study 2):
- Has fever (temperature greater than or equal to 38 degree celcius), or has had antecedent of fever for at least 2 consecutive days at the time of screening.
- One or more of the following:
- Excluded typhoid fever and and has at least 1 of the following symptoms: chest pain, sore throat, headache, muscle pain,vomiting, and diarrhea.
- Shows bleeding or facial edema.
- Does not respond to anti-malarials or antibiotics after 2 days of treatment.
- Had contact with a confirmed LF case within the last 3 weeks.
- EXCLUSION CRITERIA:
- General exclusion criteria:
- Any condition that, in the opinion of the investigator, contraindicates participation in this study, including conditions that could hinder compliance or that could place participants or study staff at increased risk.
- Pregnancy.
- Additional exclusion criteria for the clinic-based study (study 2):
- 1\. Signs or symptoms of fever-associated conditions other than LF, such as urinary tract infection, or any other infection that may cause fever.
- Co-enrollment guidelines: Participants may be co-enrolled in other studies; however, study staff should be notified of co-enrollment
Exclusion
Key Trial Info
Start Date :
December 4 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 25 2024
Estimated Enrollment :
8524 Patients enrolled
Trial Details
Trial ID
NCT03783143
Start Date
December 4 2020
End Date
July 25 2024
Last Update
August 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Icer/Mrtc/Fmos/Usttb
Bamako, Mali